AzTrials
AzTrials

Femoral Artery StenosisSFA ISRNCT02063672

Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

A study testing Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter in people with Femoral Artery Stenosis and Femoral Artery Occlusion, run by C. R. Bard at 20 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
82 participants
Where
20 sitesUnited States
Study dates
Mar 2014to Mar 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or non-pregnant female ≥18 years of age
  • Rutherford Clinical Category 2-4
  • Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting) nitinol stent(s) in the femoropopliteal artery
  • Lesion measures between 4 and 18 cm
  • Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix
  • A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography
Show all 9Show fewer
  • Successful crossing and predilatation of the target lesion with a guidewire
  • At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been (nor planned to be) revascularized
  • No other prior vascular or surgical interventions within 2 weeks before and/or planned 30 days after the protocol treatment

Who cannot join

  • Life expectancy of <1 year
  • Patient is currently participating in an investigational drug or other device study or previously enrolled in this study NOTE: Enrollment in another drug or device clinical trial during the follow up period is not allowed
  • History of stroke within 3 months
  • History of MI, thrombolysis or angina within 2 weeks of enrollment
  • Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion
  • Target lesion involves a previously placed covered stent or drug-eluting stent
Show all 10Show fewer
  • Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral configuration) in the restenotic stent
  • Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication
  • Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion
  • Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, stents, etc.)

Trial locations and contacts

20 sites in 1 country.

20 sites in 1 country

United States20 sites
  • TriHealth, Inc.

    Cincinnati, Ohio, 45220

  • Northwestern University

    Evanston, Illinois, 60208

  • Cardiology Associates

    Fairhope, Alabama, 36532

  • Hunterdon Cardiovascular Associates

    Flemington, New Jersey, 08822

  • University of Texas Medical Branch

    Galveston, Texas, 77555

  • Hattiesburg Clinic, PA

    Hattiesburg, Mississippi, 39401

  • Jackson Heart Clinic, P.A.

    Jackson, Mississippi, 39216

  • Wellmont Cardiology Services, Inc.

    Kingsport, Tennessee, 37660

  • Radiology and Imaging Specialists of Lakeland, P.A.

    Lakeland, Florida, 33805

  • Mount Sinai Medical Center

    Miami, Florida, 33140

  • Aurora Medical Group

    Milwaukee, Wisconsin, 53215

  • Yale University

    New Haven, Connecticut, 06510

  • Kansas City Vascular Foundation

    North Kansas City, Missouri, 64116

  • Minneapolis Radiology and Vascular Research Foundation

    Plymouth, Minnesota, 55441

  • The Miriam Hospital - A Lifespan Partner

    Providence, Rhode Island, 02906

  • Rex Hospital, Inc.

    Raleigh, North Carolina, 27607

  • Virginia Commonwealth University

    Richmond, Virginia, 23219

  • William Beaumont Hospital Research Institute

    Royal Oak, Michigan, 48073

  • MedStar Health Research Institute

    Washington D.C., District of Columbia, 20010

  • Metropolitan Hospital d/b/a Metro Health Hospital

    Wyoming, Michigan, 49519

Other trials in United States

About this study

Official title: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR).

Being tested
Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lutonix DCBDevice

  • Standard Uncoated Balloon Angioplasty CatheterDevice

    PTA Catheter

Study groups in NCT02063672
Study groupRoleWhat they receive
Lutonix DCBExperimentalLutonix Paclitaxel Drug Coated Balloon
Receives: Device: Lutonix DCB
PTA CatheterActive comparatorStandard Uncoated Balloon Angioplasty Catheter
Receives: Device: Standard Uncoated Balloon Angioplasty Catheter

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Primary Patency at 1 Year

    Primary patency is defined as freedom from clinically driven target lesion restenosis (TLR) and from Binary Restenosis.

    Measured: 12 Months

  2. Percentage of Participants Without Primary Safety Events

    Primary Safety Events include: All Cause Perioperative (≤30 day) Death, Index Limb Amputation, Index Limb Reintervention and Index Limb Related Death at 1 Year

    Measured: 12 Months

Secondary outcomes (18)
  1. Percentage of Participants With Device Success

    Device success is defined as, on a per device basis, the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.

    Measured: During the Index Procedure (90 mins)

  2. Percentage of Participants With Technical Success

    Technical success of the balloon procedure is defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion and a successful withdrawal of the study system with the achievement of < 30% residual percent stenosis without deployment of a bail-out stent.

    Measured: During the Index Procedure (90 mins)

  3. Percentage of Participants With Procedural Success

    Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without major adverse events (defined as occurrence of death, amputation of the target limb, or repeat revascularization of the target lesion) during the index procedure and through the hospital stay.

    Measured: During the Index Procedure (90 mins)

  4. Percentage of Participants With Primary Patency at 6 and 12 Months

    Primary Patency is defined as Freedom from CEC-adjudicated Clinically-Driven TLR and from Core laboratory-adjudicated Binary Restenosis. Binary restenosis is based on threshold Doppler peak systolic velocity ratio (PSVR) ≥ 2.5 (together with waveform analysis \& color mosaic appearance) or based on angiographic ≥ 50% diameter stenosis (if angiography is performed although not required per protocol).

    Measured: 6 months and 12 months

  5. Percentage of Participants With Secondary Patency at 6 Months and 12 Months

    Secondary patency is defined as the absence of Binary Restenosis as adjudicated by the blinded, independent core laboratory, independent of whether or not patency is re-established via an endovascular procedure.

    Measured: 6 months and 12 months

  6. Percentage of Participants Without Clinically Driven Target Lesion Revascularization (TLR)

    Clinically-driven TLR is defined as revascularization of the target vessel with evidence of target vessel diameter stenosis >50% determined by duplex ultrasound or angiography and new distal ischemic signs (worsening ABI or worsening Rutherford Category associated with the target limb or due to clinical symptoms), OR revascularization of a target vessel with an in-lesion diameter stenosis of >70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms.

    Measured: 6 months and 12 months

  7. Percentage of Participants Without Target Lesion Revascularization (TLR)

    TLR is defined as any repeat revascularization procedure (percutaneous or surgical) of the original target lesion site.

    Measured: 6 months and 12 months

  8. Percentage of Participants With Sustained Clinical Benefit Compared to Baseline

    Sustained clinical benefit is defined as an improvement in Rutherford Classification compared to baseline and freedom from target vessel revascularization. The Rutherford classification is a clinical means of describing peripheral artery disease along a seven-stage scale, with stage 0 representing asymptomatic presentation and stage 6 representing severe ischemic ulcers or frank gangrene. A decrease in units on the scale represents improvement in clinical symptoms.

    Measured: 6 months and 12 months

  9. Change of Rutherford Classification From Baseline

    The Rutherford classification is a clinical means of describing peripheral artery disease along a seven-stage scale, with stage 0 representing asymptomatic presentation and stage 6 representing severe ischemic ulcers or frank gangrene. A decrease in units on the scale represents improvement in clinical symptoms.

    Measured: 6 months and 12 months

  10. Change of Resting Ankle Brachial Index (ABI) From Baseline

    The ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium).

    Measured: 6 months and 12 months

  11. Change in Walking Impairment Questionnaire From Baseline

    The Walking Impairment Questionnaire (WIQ) is a validated questionnaire that evaluates walking ability with a focus on walking distance, walking speed, and the ability to climb stairs. Participants answer each item on a Likert scale from 0 for "unable to do" to 4 for "no difficulty", and each response is weighted based on the difficulty of the task. The overall score is determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. The overall score ranges from 0-100 with lower scores indicating lower performance.

    Measured: 6 months and 12 months

  12. Change in Quality of Life From Baseline

    EQ-5D is a standardized tool to assess patient-reported mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, or slight, moderate, severe, or extreme problems. Patients choose the appropriate level in each of the 5 dimensions, which results in a 1-digit number for each dimension. The digits for the 5 dimensions are converted into a single EQ-5D™ index score based on a set of population-based preference weights. For the U.S. general population, possible EQ-5D™ index scores range from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. A downloadable scoring file is available at: https://www.ahrq.gov/rice/EQ5Dscore.htm.

    The EQ VAS records a patient's self-rated health on a vertical visual analogue scale, where the endpoints are labeled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). A higher VAS value indicates a higher quality of life.

    Measured: 6 months and 12 Months

  13. Percentage of Participants Without Major Vascular Complications (≤30 Day)

    Freedom from major vascular complications at 30 days follow-up

    Measured: 30 Days

  14. Percentage of Participants Without All-Cause Death

    Mortality from any cause.

    Measured: 1 month, 6 months, and 12 months

  15. Percentage of Participants Without Major Limb Amputation

    Major limb amputation is defined as amputation of the lower limb above the ankle.

    Measured: 1 month, 6 months, and 12 months

  16. Percentage of Participants Without Minor Limb Amputation

    Minor limb amputation is defined as amputation of a part of the foot below the ankle.

    Measured: 1 month, 6 months, and 12 months

  17. Percentage of Participants Without Target Vessel Revascularizations (TVR)

    A TVR is defined as a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel.

    Measured: 1 month, 6 months, and 12 months

  18. Percentage of Participants Without Any Target Limb Reinterventions

    Any surgical intervention in the target limb.

    Measured: 1 month, 6 months, and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2014 (estimated)
  2. Study startMar 2014
  3. Primary completion13 Feb 2017
  4. Study completionMar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
82 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02063672
Sponsor's protocol ID
CL0018-01
Acronym
SFA ISR
Status last verified
Mar 2019
First submitted
12 Feb 2014
Last updated
11 Apr 2019
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter in people with Femoral Artery Stenosis and Femoral Artery Occlusion, run by C. R. Bard at 20 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 May 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Primary Patency at 1 Year (time frame: 12 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in